Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

NASDAQ:MBRX opened at $1.39 on Thursday. The business has a 50 day simple moving average of $1.63 and a 200 day simple moving average of $1.72. The firm has a market capitalization of $39.72 million, a P/E ratio of -2.21 and a beta of 1.84. Moleculin Biotech has a 12-month low of $1.02 and a 12-month high of $3.99.

Moleculin Biotech (NASDAQ:MBRX – Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). As a group, sell-side analysts forecast that Moleculin Biotech will post -1.01 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of Moleculin Biotech during the fourth quarter worth $87,000. Sigma Planning Corp acquired a new position in shares of Moleculin Biotech during the fourth quarter valued at about $80,000. Renaissance Technologies LLC acquired a new stake in shares of Moleculin Biotech in the 4th quarter worth about $62,000. Goldman Sachs Group Inc. acquired a new stake in shares of Moleculin Biotech in the 2nd quarter worth about $94,000. Finally, Citadel Advisors LLC grew its position in Moleculin Biotech by 174.9% in the 2nd quarter. Citadel Advisors LLC now owns 38,053 shares of the company’s stock worth $140,000 after purchasing an additional 24,210 shares in the last quarter. Hedge funds and other institutional investors own 10.57% of the company’s stock.

Moleculin Biotech Company Profile (Get Rating)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

Featured Stories